Limits...
Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis.

Shao Y, Geng Y, Gu W, Huang J, Ning Z, Pei H - Dis. Markers (2014)

Bottom Line: The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and stratified analyses were calculated to investigate the association between miR-375 expression and cancer patients OS.Our analysis results indicated that downregulation of miR-375 predicted poor OS (HR = 1.91, 95% CI 1.48-2.45, P < 0.001).Subgroup analyses showed that lower expression of miR-375 was significantly related with poor OS in patients with esophageal carcinoma (HR = 2.24, 95% CI 1.69-2.96, P < 0.001) and non-small-cell lung cancer (NSCLC) (HR = 1.71, 95% CI 1.31-2.24, P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, Jiangsu Province 213003, China.

ABSTRACT

Objective: Recently, many studies have shown that microRNAs (miRNA) exhibit altered expression in various cancers and may play an important role as prognostic biomarker of cancers. We performed a meta-analysis to evaluate the impact of miR-375 expression in solid tumors on patients' overall survival (OS).

Methods: Studies were identified by searching PubMed, Embace, and Cochrane Library (last search update was in May 2014) and were assessed by further quality evaluation. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and stratified analyses were calculated to investigate the association between miR-375 expression and cancer patients OS.

Results: Our analysis results indicated that downregulation of miR-375 predicted poor OS (HR = 1.91, 95% CI 1.48-2.45, P < 0.001). Subgroup analyses showed that lower expression of miR-375 was significantly related with poor OS in patients with esophageal carcinoma (HR = 2.24, 95% CI 1.69-2.96, P < 0.001) and non-small-cell lung cancer (NSCLC) (HR = 1.71, 95% CI 1.31-2.24, P < 0.001).

Conclusions: The findings from this meta-analysis suggest that miR-375 expression is associated with OS of patients with malignant tumors and could be a useful clinical prognostic biomarker.

Show MeSH

Related in: MedlinePlus

Forest plot of the relationship between lower miR-375 expression and overall survival (OS) in esophageal carcinoma and NSCLC with fixed-effects model.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4227452&req=5

fig3: Forest plot of the relationship between lower miR-375 expression and overall survival (OS) in esophageal carcinoma and NSCLC with fixed-effects model.

Mentions: Considering the heterogeneity among these studies, the effect of miR-375 expression was further evaluated by subgroup analysis. The subgroups were classified according to the main characteristics such as tumor type, source of miRNA, miRNA assay method, type of method used to obtain the HR, patient origin, and analysis type. In the subgroup of tumor type, we found the downregulation of miR-375 was significantly associated with worse OS in esophageal carcinoma (HR = 2.24, 95% CI 1.69–2.96; P < 0.001; fixed-effects model) and NSCLC (HR = 1.71, 95% CI 1.31–2.24; fixed-effects model), without any heterogeneity in the data (I2 = 1.9%, P = 0.415; I2 = 0.0%,P = 0.554, resp.) (Table 2 and Figure 3). There was only one study that evaluated the association between lower miR-375 expression and OS in HNSCC, gastric cancer, breast cancer, PDAC, and glioma, respectively, and therefore, these tumors were defined as “other cancers.” Combined data from these five studies showed that decreased miR-375 expression was not correlated with poor OS (HR = 1.59, 95% CI 0.71–3.58; random-effects model) and with significant statistical heterogeneity (I2 = 74.5%, P = 0.004) (Table 2). The association between lower miR-375 expression and worse OS outcome was statistically significant in other subgroups, including HR reported in text (HR = 1.97, 95% CI 1.57–2.47, fixed-effects model; P = 0.346 for heterogeneity test, I2 = 10.8%), miR-375 assay by qRT-PCR (HR = 1.88, 95% CI 1.42–2.48, random-effects model; P = 0.026 for heterogeneity test, I2 = 46.2%), tissue-source of miRNA (HR = 2.16, 95% CI 1.73–2.71, fixed-effects model; P = 0.295 for heterogeneity test, I2 = 15.7%), multivariate analysis (HR = 1.97, 95% CI 1.57–2.47, fixed-effects model; P = 0.346 for heterogeneity test, I2 = 10.8%), Chinese patients (HR = 1.96, 95% CI 1.62–2.37, fixed-effects model; P = 0.295 for heterogeneity test, I2 = 15.7%), and American patients (HR = 1.97, 95% CI 1.30–2.99, fixed-effects model; P = 0.180 for heterogeneity test, I2 = 36.2%) (Table 2). The expression of miR-375 did not show prognostic impact in subgroups of HRs by data extrapolated, univariate analysis, and blood-source of miRNA. The subgroup of miR-375 detected by MISH only included one study; therefore the result related entirely to the individual study.


Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis.

Shao Y, Geng Y, Gu W, Huang J, Ning Z, Pei H - Dis. Markers (2014)

Forest plot of the relationship between lower miR-375 expression and overall survival (OS) in esophageal carcinoma and NSCLC with fixed-effects model.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4227452&req=5

fig3: Forest plot of the relationship between lower miR-375 expression and overall survival (OS) in esophageal carcinoma and NSCLC with fixed-effects model.
Mentions: Considering the heterogeneity among these studies, the effect of miR-375 expression was further evaluated by subgroup analysis. The subgroups were classified according to the main characteristics such as tumor type, source of miRNA, miRNA assay method, type of method used to obtain the HR, patient origin, and analysis type. In the subgroup of tumor type, we found the downregulation of miR-375 was significantly associated with worse OS in esophageal carcinoma (HR = 2.24, 95% CI 1.69–2.96; P < 0.001; fixed-effects model) and NSCLC (HR = 1.71, 95% CI 1.31–2.24; fixed-effects model), without any heterogeneity in the data (I2 = 1.9%, P = 0.415; I2 = 0.0%,P = 0.554, resp.) (Table 2 and Figure 3). There was only one study that evaluated the association between lower miR-375 expression and OS in HNSCC, gastric cancer, breast cancer, PDAC, and glioma, respectively, and therefore, these tumors were defined as “other cancers.” Combined data from these five studies showed that decreased miR-375 expression was not correlated with poor OS (HR = 1.59, 95% CI 0.71–3.58; random-effects model) and with significant statistical heterogeneity (I2 = 74.5%, P = 0.004) (Table 2). The association between lower miR-375 expression and worse OS outcome was statistically significant in other subgroups, including HR reported in text (HR = 1.97, 95% CI 1.57–2.47, fixed-effects model; P = 0.346 for heterogeneity test, I2 = 10.8%), miR-375 assay by qRT-PCR (HR = 1.88, 95% CI 1.42–2.48, random-effects model; P = 0.026 for heterogeneity test, I2 = 46.2%), tissue-source of miRNA (HR = 2.16, 95% CI 1.73–2.71, fixed-effects model; P = 0.295 for heterogeneity test, I2 = 15.7%), multivariate analysis (HR = 1.97, 95% CI 1.57–2.47, fixed-effects model; P = 0.346 for heterogeneity test, I2 = 10.8%), Chinese patients (HR = 1.96, 95% CI 1.62–2.37, fixed-effects model; P = 0.295 for heterogeneity test, I2 = 15.7%), and American patients (HR = 1.97, 95% CI 1.30–2.99, fixed-effects model; P = 0.180 for heterogeneity test, I2 = 36.2%) (Table 2). The expression of miR-375 did not show prognostic impact in subgroups of HRs by data extrapolated, univariate analysis, and blood-source of miRNA. The subgroup of miR-375 detected by MISH only included one study; therefore the result related entirely to the individual study.

Bottom Line: The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and stratified analyses were calculated to investigate the association between miR-375 expression and cancer patients OS.Our analysis results indicated that downregulation of miR-375 predicted poor OS (HR = 1.91, 95% CI 1.48-2.45, P < 0.001).Subgroup analyses showed that lower expression of miR-375 was significantly related with poor OS in patients with esophageal carcinoma (HR = 2.24, 95% CI 1.69-2.96, P < 0.001) and non-small-cell lung cancer (NSCLC) (HR = 1.71, 95% CI 1.31-2.24, P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, Jiangsu Province 213003, China.

ABSTRACT

Objective: Recently, many studies have shown that microRNAs (miRNA) exhibit altered expression in various cancers and may play an important role as prognostic biomarker of cancers. We performed a meta-analysis to evaluate the impact of miR-375 expression in solid tumors on patients' overall survival (OS).

Methods: Studies were identified by searching PubMed, Embace, and Cochrane Library (last search update was in May 2014) and were assessed by further quality evaluation. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and stratified analyses were calculated to investigate the association between miR-375 expression and cancer patients OS.

Results: Our analysis results indicated that downregulation of miR-375 predicted poor OS (HR = 1.91, 95% CI 1.48-2.45, P < 0.001). Subgroup analyses showed that lower expression of miR-375 was significantly related with poor OS in patients with esophageal carcinoma (HR = 2.24, 95% CI 1.69-2.96, P < 0.001) and non-small-cell lung cancer (NSCLC) (HR = 1.71, 95% CI 1.31-2.24, P < 0.001).

Conclusions: The findings from this meta-analysis suggest that miR-375 expression is associated with OS of patients with malignant tumors and could be a useful clinical prognostic biomarker.

Show MeSH
Related in: MedlinePlus